🇪🇺 Adjunctive asenapine in European Union

EMA authorised Adjunctive asenapine on 1 September 2010

Marketing authorisation

EMA — authorised 1 September 2010

  • Application: EMEA/H/C/001177
  • Marketing authorisation holder: Organon N.V.
  • Local brand name: Sycrest
  • Indication: Sycrest is indicated for the treatment of moderate to severe manic episodes associated with bipolar I disorder in adults.
  • Status: approved

Read official source →

Adjunctive asenapine in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Other Psychiatry approved in European Union

Frequently asked questions

Is Adjunctive asenapine approved in European Union?

Yes. EMA authorised it on 1 September 2010.

Who is the marketing authorisation holder for Adjunctive asenapine in European Union?

Organon N.V. holds the EU marketing authorisation.